share_log

iBio Inc | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

iBio Inc | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

iBio Inc | S-3/A：特定交易注册声明(修正)
美股SEC公告 ·  07/25 17:09
Moomoo AI 已提取核心信息
iBio Inc., a biotechnology company, has filed an amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 25, 2024, for the potential sale of up to $150,000,000 in various securities. The securities may include common stock, preferred stock, debt securities, warrants, or units. The company has entered into an At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC to offer up to $7,350,000 of common stock. The sales may be made through 'at the market' offerings, and the proceeds are intended for working capital and general corporate purposes, which may include acquisitions, licensing, investments, or repurchasing securities. iBio Inc. has not specified the number of shares or the price range for the offering. The company's common stock is listed on the NYSE American under the symbol 'IBIO'.
iBio Inc., a biotechnology company, has filed an amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 25, 2024, for the potential sale of up to $150,000,000 in various securities. The securities may include common stock, preferred stock, debt securities, warrants, or units. The company has entered into an At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC to offer up to $7,350,000 of common stock. The sales may be made through 'at the market' offerings, and the proceeds are intended for working capital and general corporate purposes, which may include acquisitions, licensing, investments, or repurchasing securities. iBio Inc. has not specified the number of shares or the price range for the offering. The company's common stock is listed on the NYSE American under the symbol 'IBIO'.
生物技术公司ibio inc已于2024年7月25日向美国证券交易所（SEC）提交了一份注册声明修正案，以便可能出售高达1.5亿美元的各种证券。这些证券可能包括普通股、优先股、债务证券、权证或单位。该公司已经与Chardan Capital Markets，LLC和Craig-Hallum Capital Group LLC签订了一份市场发行销售协议，以提供高达735万美元的普通股。销售可能通过“市场”发行，收益预期用于工作资本和一般公司目的，包括收购、许可、投资或回购证券。ibio inc没有指定发行的股份数量或价格区间。该公司的普通股在纽约证券交易所美国版（NYSE American）上市，股票代码为“IBIO”。
生物技术公司ibio inc已于2024年7月25日向美国证券交易所（SEC）提交了一份注册声明修正案，以便可能出售高达1.5亿美元的各种证券。这些证券可能包括普通股、优先股、债务证券、权证或单位。该公司已经与Chardan Capital Markets，LLC和Craig-Hallum Capital Group LLC签订了一份市场发行销售协议，以提供高达735万美元的普通股。销售可能通过“市场”发行，收益预期用于工作资本和一般公司目的，包括收购、许可、投资或回购证券。ibio inc没有指定发行的股份数量或价格区间。该公司的普通股在纽约证券交易所美国版（NYSE American）上市，股票代码为“IBIO”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息